Psychiatry and Neurology, Neurology · Overland Park, KS
NPI
1629230479
Since 2008
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
12140 Nall Ave, Suite 230
Overland Park, KS, 66209
Phone (913) 661-9448
Groups this clinician bills Medicare through
Medicare paid, 2024
$94K
975 services
Medicare patients, 2024
461
Average age 73
Drug cost, 2024
$6.0M
3,504 prescriptions
Company payments, 2025
$3,547
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David F Clark was code 99214 (office e&m - established), 274 times for 187 patients. In total David F Clark billed 975 services in 28 codes, and Medicare paid $94K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-06-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 274 | 187 | $85.95 | $24K |
| 95886 Electrical Nerve Conductivity | Office | 218 | 117 | $69.34 | $15K |
| 99215 Office E&M - Established | Office | 114 | 91 | $124.17 | $14K |
| 99204 Office E&M - New | Office | 72 | 72 | $117.91 | $8,489 |
| 95911 Electrical Nerve Conductivity | Office | 47 | 47 | $154.27 | $7,250 |
| 99483 Office/Outpatient Services | Office | 45 | 39 | $169.64 | $7,634 |
| 95910 Electrical Nerve Conductivity | Office | 38 | 38 | $120.20 | $4,568 |
| 99205 Office E&M - New | Office | 21 | 21 | $161.70 | $3,396 |
| 99203 Office E&M - New | Office | 17 | 17 | $66.65 | $1,133 |
| 99213 Office E&M - Established | Office | 17 | 17 | $62.60 | $1,064 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 12 | 12 | $0.79 | $9.42 |
| 95909 Electrical Nerve Conductivity | Office | 12 | 12 | $97.79 | $1,174 |
| 96372 Injection Administration | Office | 12 | 12 | $7.84 | $94.07 |
By year: 2022 $102K for 1,036 services; 2023 $105K for 1,087 services; 2024 $94K for 975 services.
Medicare prescription drug claims, 2024
In 2024, the drug David F Clark prescribed most often to Medicare patients was Pregabalin, with 219 prescriptions and refills. In total David F Clark wrote 3,504 Medicare prescriptions that cost $6.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pregabalin Generic | 219 | 434 | 90 | $8,391 |
| Gabapentin Generic | 211 | 465 | 81 | $5,336 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 201 | 446 | 64 | $8,307 |
| Lamotrigine Generic | 197 | 449 | 46 | $6,228 |
| Memantine Hcl Generic | 189 | 473 | 55 | $5,077 |
| Levetiracetam Generic | 168 | 392 | 49 | $8,546 |
| Duloxetine Hcl Generic | 168 | 308 | 47 | $6,150 |
| Topiramate Generic | 150 | 330 | 35 | $3,313 |
| Donepezil Hcl Generic | 112 | 278 | 34 | $1,281 |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 89 | 92 | Under 11 | $583K |
| Carbamazepine Generic | 75 | 129 | 21 | $7,545 |
| Propranolol Hcl Generic | 72 | 181 | 22 | $3,070 |
| Primidone Generic | 63 | 168 | 23 | $1,927 |
| Clonazepam Generic | 60 | 74 | 12 | $814 |
| Baclofen Generic | 58 | 114 | 19 | $4,441 |
Brand drugs: - claims; generic drugs: 2,990 claims; opioid claims: 24.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David F Clark $3,547 ($3,547 in general payments such as food, travel and fees) from 33 companies. The largest payer was UCB, Inc. with $448.
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. UCB.BR | 15 | $448 |
| Abbvie Inc. ABBV | 17 | $353 |
| Pfizer Inc. PFE | 26 | $286 |
| Biogen, Inc. BIIB | 13 | $229 |
| Novartis Pharmaceuticals Corporation NVS | 14 | $187 |
| Vanda Pharmaceuticals Inc. VNDA | 7 | $185 |
| Jazz Pharmaceuticals Inc. JAZZ | 7 | $185 |
| EMD Serono, Inc. MRK.DE | 7 | $149 |
| Genentech USA, Inc. ROG.SW | 6 | $144 |
| Genzyme Corporation SNY | 4 | $124 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.